Updated: March 26, 2026
Alternatives to Amjevita If You Can't Fill Your Prescription
Author
Peter Daggett

Summarize with AI
Can't fill your Amjevita prescription? Explore FDA-approved alternatives including other adalimumab biosimilars and TNF inhibitors that treat the same conditions.
Alternatives to Amjevita If You Can't Fill Your Prescription
If you've been prescribed Amjevita (Adalimumab-Atto) but can't fill your prescription — whether because of cost, availability, or insurance issues — you have options. Several FDA-approved alternatives work the same way and treat the same conditions.
Before switching medications, always talk to your doctor. But knowing what's out there can help you have a more productive conversation with your healthcare team. This guide covers the most common alternatives to Amjevita available in 2026.
What Is Amjevita and How Does It Work?
Amjevita is a biosimilar to Humira (Adalimumab), made by Amgen. It was the first Humira biosimilar to launch in the U.S. in January 2023. The active ingredient, Adalimumab-Atto, is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a protein that drives inflammation in autoimmune diseases.
By neutralizing TNF-α, Amjevita reduces inflammation and helps control symptoms of conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and more. For a deeper dive, read our guide to how Amjevita works.
Because Amjevita is a biosimilar, its alternatives fall into two main categories: other Adalimumab biosimilars (which are nearly identical) and other TNF inhibitors (which work through a similar mechanism but are different drugs).
Adalimumab Biosimilars: Near-Identical Alternatives
The easiest switch from Amjevita is to another Adalimumab biosimilar. These medications contain a version of Adalimumab that has been shown to have no clinically meaningful differences from the reference product (Humira). They treat all the same conditions and are dosed the same way.
Hadlima (Adalimumab-Bwwd)
Manufacturer: Organon / Samsung Bioepis
Hadlima is an Adalimumab biosimilar available in prefilled syringes and autoinjector pens. It's approved for all the same indications as Amjevita and Humira. Hadlima has gained formulary preference with several major insurance plans, which means it may be easier to get covered and find in stock compared to other biosimilars.
Key difference: Hadlima may be your insurer's preferred Adalimumab product. If Amjevita isn't covered, Hadlima might be.
Hyrimoz (Adalimumab-Adaz)
Manufacturer: Sandoz
Hyrimoz is another interchangeable Adalimumab biosimilar, meaning pharmacists can substitute it for Humira without a new prescription in most states. The high-concentration (HC) citrate-free version of Hyrimoz has been gaining market share. Several PBMs and insurance plans have placed Hyrimoz on preferred formulary tiers.
Key difference: Hyrimoz HC (high-concentration, citrate-free) offers the same injection convenience as Amjevita and may be preferred by your insurance plan.
Cyltezo (Adalimumab-Adbm)
Manufacturer: Boehringer Ingelheim
Cyltezo was the first Adalimumab biosimilar to receive FDA interchangeability designation. It's available in both branded and unbranded versions. The unbranded Adalimumab-Adbm is often one of the lowest-cost options, with GoodRx prices significantly below brand-name Humira.
Key difference: Cyltezo and its unbranded version can be among the most affordable Adalimumab options, especially for cash-pay patients.
Simlandi (Adalimumab-Ryvk)
Manufacturer: Teva
Simlandi is a newer Adalimumab biosimilar that entered the market more recently. It's available in a high-concentration, citrate-free autoinjector pen and prefilled syringe. As a newer entrant, Simlandi may offer competitive pricing and savings programs.
Key difference: As a newer biosimilar, Simlandi may have aggressive copay assistance programs for patients switching from other products.
Other TNF Inhibitors: Different Drugs, Similar Approach
If Adalimumab biosimilars aren't working for you — because of side effects, insurance restrictions, or other reasons — your doctor may consider a different TNF inhibitor. These are not biosimilars to Humira; they are separate biologic drugs that also block TNF-α but have different molecular structures.
Enbrel (Etanercept)
Enbrel is a TNF inhibitor that works differently from Adalimumab — it's a fusion protein rather than a monoclonal antibody. It's FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis. Enbrel is typically injected once or twice weekly.
Note: Enbrel is not approved for Crohn's disease or ulcerative colitis, so it's only an alternative for certain conditions.
Remicade (Infliximab) and Its Biosimilars
Infliximab is another TNF inhibitor, but it's administered as an intravenous (IV) infusion rather than a subcutaneous injection. It's approved for rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Several Infliximab biosimilars are available, including Inflectra and Renflexis.
Note: Because Infliximab requires IV infusions (usually every 6-8 weeks at an infusion center), it's a bigger lifestyle change compared to self-injecting at home with Amjevita.
How to Decide Which Alternative Is Right for You
When choosing an alternative to Amjevita, consider these factors:
- Insurance coverage: Check which Adalimumab biosimilar your plan prefers. Switching to a preferred product can save you hundreds or thousands of dollars per year.
- Availability: Use Medfinder to check which alternatives are in stock near you.
- Cost: Compare out-of-pocket costs across biosimilars. Manufacturer copay programs vary — some offer $0 copays for eligible patients. See our guide to saving money on Amjevita for details on assistance programs.
- Your condition: Not all TNF inhibitors are approved for all conditions. Make sure any alternative is FDA-approved for your specific diagnosis.
- Injection preference: If you prefer a pen over a syringe (or vice versa), check which delivery devices each biosimilar offers.
Final Thoughts
If you can't fill your Amjevita prescription, you're not out of options. Multiple Adalimumab biosimilars are available that work the same way and treat the same conditions. For some patients, a different TNF inhibitor might be the better choice.
Start by checking with your insurance to see which products are covered, then use Medfinder to locate available options near you. And always talk to your doctor before making any changes to your treatment. Staying on an effective biologic therapy is the most important thing — the specific brand is secondary.
For more information, read our guides on what Amjevita is and how it's used and how to find Amjevita in stock.
Frequently Asked Questions
Yes. All FDA-approved Adalimumab biosimilars (Hadlima, Hyrimoz, Cyltezo, Simlandi) have been shown in clinical trials to have no clinically meaningful differences in safety or effectiveness compared to Humira. They are approved for the same indications and dosed the same way.
Pharmacists can substitute interchangeable biosimilars (like Amjevita, Cyltezo, or Hyrimoz) for Humira without a new prescription in most states. However, switching between different biosimilars (e.g., from Amjevita to Hadlima) typically requires a new prescription from your doctor.
Clinical studies have not shown increased side effects when switching between Adalimumab biosimilars. All approved biosimilars have similar safety profiles. Some patients may notice minor differences in injection experience (such as injection site reactions) due to different formulations, but these are generally mild.
If your insurance won't cover any Adalimumab biosimilar, ask your doctor about patient assistance programs. Amgen's Safety Net Foundation offers free Amjevita to qualifying uninsured or underinsured patients. Other manufacturers have similar programs. Your doctor may also appeal the insurance denial or consider a different class of biologic.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsRelated articles
32,238 have already found their meds with Medfinder.
Start your search today.

![Who Has Vyvanse in Stock Near You? Find It Today [2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1079f61f167dcbc2ed5f1da17a0dcb0b7166357e-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)



